Recommendations for the Treatment of Children With Burkitt's Lymphoma

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorFrench Africa Pediatric Oncology Group

About this trial

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

All Children with a Burkitt's Lymhoma.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • OBSERVATIONAL

    Other intervention

    OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE

Treatment groups

1,000 Participants
are divided into 1 treatment group
Group A: All children with Burkitt lymphoma and in 2 units the addition of Rituximab1 intervention

Trial outcomes

Primary outcomes

1

Evaluation of the number of cases with local disease.

evaluating the initial clinical reports and later histological reports to confirm the diagnosis and the stage.

Time frame
5 years
2

Evaluation of the number of cases by stage at the time of diagnosis.

evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.

Time frame
5 Years
3

Evaluating the treatment given.

Comparison of treatment given and recommended treatment.

Time frame
5 Years
4

Evaluating the follow up after treatment.

How many children alive or dead after treatment

Time frame
5 Years

Secondary outcomes

1

Application of therapeutic recommendations

Evaluations of the correct application of recommendations

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.